Stage 0 : Cancer cells remain inside the breast duct, without invasion into normal adjacent breast tissue. Can be treated with NUTAS
Stage IA : The tumor measures up to 2 cm
AND the cancer has not spread outside the breast; no lymph nodes are involved.
There is no tumor in the breast; instead, small groups of cancer cells — larger than 0.2 millimeter but not larger than 2 millimeters – are found in the lymph nodes. Can be treated with NUTAS
Stage IB : There is a tumor in the breast that is no larger than 2 centimeters, and there are small groups of cancer cells – larger than 0.2 millimeter but not larger than 2 millimeters – in the lymph nodes.
No tumor can be found in the breast, but cancer cells are found in the axillary lymph nodes (the lymph nodes under the arm) Can be treated wi
IIA : The tumor measures 2 centimeters or smaller and has spread to the axillary lymph nodes
The tumor is larger than 2 but no larger than 5 centimeters and has not spread to the axillary lymph nodes.
The tumor is larger than 2 but no larger than 5 centimeters and has spread to the axillary lymph nodes
Can be treated with NUTAS
Stage IIB : The tumor is larger than 5 centimeters but has not spread to the axillary lymph nodes.
Stage IIIB : The tumor may be any size and has spread to the chest wall and/or skin of the breast and may have spread to axillary lymph nodes that are clumped together or sticking to other structures, or cancer may have spread to lymph nodes near the breastbone.
Inflammatory breast cancer is considered at least stage IIIB. Can be treated with NUTAS
Stage IIIC : There may either be no sign of cancer in the breast or a tumor may be any size and may have spread to the chest wall and/or the skin of the breast
the cancer has spread to lymph nodes either above or below the collarbone
the cancer may have spread to axillary lymph nodes or to lymph nodes near the breastbone.
Can be treated with NUTAS
Stage IV : The cancer has spread — or metastasized — to other parts of the body
Can be treated with NUTAS + CHEMO + RADIOTHERAPY, etc.
Treatment of non-invasive (stage 0) breast cancer
Stage 0 includes lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS), which are treated very differently.
Since this is not a true cancer or pre-cancer, no immediate or active treatment is recommended for most women with LCIS. But because having LCIS increases your risk of developing invasive cancer later on, close follow-up is very important. This usually includes a yearly mammogram and a clinical breast exam. Close follow-up of both breasts is important because women with LCIS in one breast have the same increased risk of developing cancer in either breast. Although there is not enough evidence to recommend routine use of magnetic resonance imaging (MRI) in addition to mammograms for all women with LCIS, it is reasonable for these women to talk with their doctors about their other risk factors and the benefits and limits of being screened yearly with MRI.
Women with LCIS may also want to consider taking tamoxifen or raloxifene (Evista) to reduce their risk of breast cancer or taking part in a clinical trial for breast cancer prevention. For more information on drugs to reduce breast cancer risk see our document, Medicines to Reduce Breast Cancer Risk. They might also wish to discuss other possible prevention strategies (such as reaching an optimal body weight or starting an exercise program) with their doctor. Some women with LCIS choose to have a bilateral simple mastectomy (removal of both breasts but not axillary lymph nodes) to reduce their risk of breast cancer, especially if they have other risk factors, such as a strong family history. A woman also may consider immediate or delayed breast reconstruction.
In most cases, a woman with DCIS can choose between breast-conserving surgery (BCS) and simple mastectomy. BCS is usually followed by radiation therapy. Lymph node removal (most often a sentinel lymph node biopsy) is not always needed. It may be done if the doctor thinks that a woman with DCIS may also have an area of invasive cancer. The risk of an area of DCIS containing invasive cancer goes up with tumor size and nuclear grade. Many doctors will do a sentinel lymph node biopsy if a mastectomy is done for DCIS. This is because if an area of invasive cancer is found in the tissue removed during a mastectomy, the doctor won’t be able to go back and do a sentinel lymph node procedure later, and so may have to do a full axillary lymph node dissection.
Radiation therapy given after BCS lowers the chance of the cancer coming back in the same breast (as more DCIS or as an invasive cancer). BCS without radiation therapy is not a standard treatment, but might be an option for certain women who had small areas of low-grade DCIS that were removed with large enough cancer-free surgical margins. But most women who have BCS for DCIS will require radiation therapy.
Mastectomy may be necessary if the area of DCIS is very large, if the breast has several areas of DCIS, or if BCS cannot completely remove the DCIS (that is, the BCS specimen and re-excision specimens have cancer cells in or near the surgical margins). Women having a mastectomy for DCIS may choose to have reconstruction immediately or later.
If the DCIS is estrogen receptor−positive, treatment with tamoxifen for 5 years after surgery can lower the risk of another DCIS or invasive cancer developing in either breast. Women may want to discuss the pros and cons of this option with their doctors.
Treatment of invasive breast cancer, by stage
Breast-conserving surgery (BCS) is often appropriate for earlier-stage invasive breast cancers if the cancer is small enough, although mastectomy is also an option. If the cancer is too large, a mastectomy will be needed, unless pre-operative (neoadjuvant) chemotherapy (chemo) can shrink the tumor enough to allow BCS. In either case, one or more underarm lymph nodes will need to be checked for cancer. Radiation will be needed for almost all patients who have BCS and some who have mastectomy. Adjuvant systemic therapy after surgery is typically recommended for all cancers larger than 1 cm (about 1/2 inch) across, and also sometimes for smaller tumors.
These cancers are still relatively small and either have not spread to the lymph nodes (N0) or have a tiny area of cancer spread in the sentinel lymph node (N1mi).
Local therapy: Stage I cancers can be treated with either BCS (lumpectomy, partial mastectomy) or mastectomy. The lymph nodes will also need to be evaluated, with a sentinel lymph node biopsy or an axillary lymph node dissection. Breast reconstruction can be done either at the same time as surgery or later . Radiation therapy is usually given after BCS. Women may consider BCS without radiation therapy if they are at least 70 years old and ALL of the following are true:
The tumor was 2 cm or less across and it has been completely removed.
The tumor contains hormone receptors and hormone therapy is given.
None of the lymph nodes removed contained cancer.
Some women who do not meet these criteria may be tempted to avoid radiation, but studies have shown that not getting radiation increases the chances of the cancer coming back.
Adjuvant systemic therapy: Most doctors will discuss the pros and cons of adjuvant hormone therapy (either tamoxifen, an aromatase inhibitor, or one following the other) with all women who have a hormone receptor–positive (estrogen or progesterone) breast cancer, no matter how small the tumor. Women with tumors larger than 0.5 cm (about ¼ inch) across may be more likely to benefit from it. If the tumor is smaller than 1 cm (about ½ inch) across, adjuvant chemo is not usually offered. Some doctors may suggest chemo if a cancer smaller than 1 cm has any unfavorable features (such as being high-grade, hormone receptor–negative, HER2-positive, or having a high score on a gene panel like Oncotype Dx). Adjuvant chemo is usually recommended for larger tumors
These cancers are larger and/or have spread to a few nearby lymph nodes.
Local therapy: Surgery and radiation therapy options for stage II tumors are similar to those for stage I tumors, except that for stage II, radiation therapy to the chest wall may be considered even after mastectomy if the tumor is large (more than 5 cm across) or cancer cells are found in several lymph nodes.
Adjuvant systemic therapy: Adjuvant systemic therapy is recommended for women with stage II breast cancer. It may be hormone therapy, chemo, trastuzumab, or some combination of these, depending on the patient’s age, estrogen-receptor status, and HER2/neu status. See the following section for more information on adjuvant therapy.
Neoadjuvant therapy: An option for some women who would like to have BCS, but the surgeon thinks the tumor is too large to have a good result, is to have systemic treatment before surgery to shrink the tumor. This is called neoadjuvant therapy and it can include chemo or hormone therapy. For HER2-positive tumors, the targeted drug trastuzumab is also used, sometimes along with pertuzumab (Perjeta).
If the neoadjuvant treatment shrinks the tumor enough, women may then be able to have BCS (such as lumpectomy) followed by radiation therapy. More adjuvant therapy may also be given after surgery.
If the tumor does not shrink enough for BCS, then mastectomy may be required. Adjuvant therapy may also be given after surgery, but would likely be with different drugs, since the tumor did not shrink with the first set given. Radiation therapy may be given after surgery, as well.
A woman’s chance for survival from breast cancer does not seem to be affected by whether she gets chemo before or after her breast surgery.
For a cancer to be stage III, the tumor must be large (greater than 5 cm or about 2 inches across) or growing into nearby tissues (the skin over the breast or the muscle underneath), or the cancer has spread to many nearby lymph nodes. Local treatment for some stage III breast cancers is largely the same as that for stage II breast cancers. Tumors that are small enough (and have not grown into nearby tissues) may be removed by BCS (such as lumpectomy) which is followed by radiation therapy. Otherwise, the treatment is mastectomy (with or without breast reconstruction). Sentinel lymph node biopsy may be an option for some patients, but most require an axillary lymph node dissection. Surgery is usually followed by adjuvant systemic chemotherapy, and/or hormone therapy, and/or trastuzumab. Radiation after mastectomy is often recommended.
Often, stage III cancers are treated with chemo before surgery (neoadjuvant chemo). For HER2-positive tumors, the targeted drug trastuzumab is given as well, sometimes along with pertuzumab. This may shrink the tumor enough to allow BCS. Otherwise, a mastectomy is done. Usually an axillary lymph node dissection is done as well. Immediate reconstruction may be an option for some, but reconstruction is often delayed until after radiation therapy, which is often given even if a mastectomy is done. Adjuvant chemo may also be given, with trastuzumab added to chemo for HER2-positive cancers. Adjuvant hormone therapy is offered to all women with hormone receptor–positive breast cancers.
Some inflammatory breast cancers are stage III. They are treated with neoadjuvant chemo (with trastuzumab and sometimes pertuzumab if the cancer is HER2-positive). If the cancer doesn’t shrink with chemo, radiation may be given. This is followed by a mastectomy and axillary lymph node dissection. Then adjuvant treatment with chemo (and trastuzumab if the cancer is HER2-positive), radiation therapy (if it wasn’t given before surgery), and hormone therapy (if the cancer is hormone receptor−positive) is given.
Adjuvant drug therapy for stages I to III breast cancer
Adjuvant drug therapy may be recommended, based on the tumor’s size, spread to lymph nodes, and other prognostic features. If it is, you may get chemo, trastuzumab (Herceptin), hormone therapy, or some combination of these.
Hormone therapy: Hormone therapy is not likely to be effective for women with hormone receptor-negative tumors. Hormone therapy is frequently offered to all women with hormone receptor–positive invasive breast cancer regardless of the size of the tumor or the number of lymph nodes with cancer cells.
Women who haven’t gone through menopause and have hormone receptor–positive tumors are most often treated with tamoxifen, which block the effects of estrogen being made by the ovaries. Some doctors also give a luteinizing hormone-releasing hormone (LHRH) analog, which temporarily stops the ovaries from functioning. Another (permanent) option is surgical removal of the ovaries (oophorectomy). Still, it is not clear that removing the ovaries or stopping them from working helps tamoxifen work better for cancers that have been removed completely. If the woman becomes post-menopausal within 5 years of starting tamoxifen (either naturally or because her ovaries are removed), she may be switched from tamoxifen to an aromatase inhibitor.
Sometimes a woman will stop having periods after chemotherapy or while on tamoxifen. But this does not necessarily mean she is truly post-menopausal. The woman’s doctor can check the levels of certain hormones to determine her menopausal status. This is important because the aromatase inhibitors will not help if her ovaries are still working (and she is pre-menopausal).
Women have gone through menopause and who have hormone receptor–positive tumors will generally get adjuvant hormone therapy either with an aromatase inhibitor (typically for 5 years), or with tamoxifen for 2 to 5 years followed by an aromatase inhibitor for 3 to 5 more years. For women who can’t take aromatase inhibitors, an alternative is tamoxifen for 5 years. Women who had their uterus removed (a hysterectomy) but still have their ovaries may need to have blood tests to check hormone levels to see if they have gone through menopause.
If chemo is to be given as well, hormone therapy is usually not started until after chemo is completed.
Chemotherapy: Chemo is usually recommended for all women with an invasive breast cancer whose tumor is hormone receptor-negative, and for women with hormone receptor−positive tumors who might additionally benefit from having chemo along with their hormone therapy, based on the stage and characteristics of their tumor. Adjuvant chemo can decrease the risk of the cancer coming back, but it does not remove the risk completely. Before deciding if it’s right for you, it is important to understand the chance of your cancer returning and how much adjuvant therapy will decrease that risk.
Your doctor should discuss what specific drug regimens are best for you based on your cancer, its stage, your other health issues, and your preferences. The typical chemo regimens are listed in the chemotherapy section. The length of these regimens usually ranges from 3 to 6 months. In some cases, dose-dense chemo may be used.
Trastuzumab (Herceptin): Women who have HER2-positive cancers are usually given trastuzumab along with chemo as part of their treatment. After the chemo is finished, the trastuzumab is continued to complete a year of treatment.
Because trastuzumab can lead to heart problems, heart function is watched closely during treatment with tests such as echocardiograms or MUGA scans.
Stage IV cancers have spread beyond the breast and lymph nodes to other parts of the body. Breast cancer most commonly spreads to the bones, liver, and lung. As the cancer progresses, it may spread to the brain, but it can affect any organ, even the eye.
Although surgery and/or radiation may be useful in some situations (see below), systemic therapy is the main treatment. Depending on many factors, this may consist of hormone therapy, chemotherapy, targeted therapies, or some combination of these treatments. Treatment can shrink tumors, improve symptoms, and help patients live longer, but it isn’t able to cure these cancers (make the cancer go away and stay away).
Trastuzumab may help women with HER2-positive cancers live longer if it is given with the first chemo for stage IV disease. Trastuzumab can also be given with the hormone therapy drug letrozole. Other options include ado-trastuzumab emtansine (Kadcyla) or giving pertuzumab with chemo and trastuzumab. Treatment with ado-trastuzumab emtansine continues until the cancer starts growing again. It is not clear how long treatment with trastuzumab (with or without pertuzumab) should continue.
All of the systemic therapies given for breast cancer—hormone therapy, chemo, and targeted therapies—have possible side effects, which were described in previous sections. Your doctor will explain to you the benefits and risks of these treatments before prescribing them.
Radiation therapy and/or surgery may also be used in certain situations, such as:
When the breast tumor is causing an open wound in the breast (or chest)
To treat a small number of metastases in a certain area
To prevent bone fractures
When an area of cancer spread is pressing on the spinal cord
To treat a blockage in the liver
To provide relief of pain or other symptoms
When the cancer has spread to the brain
If your doctor recommends such local treatments, it is important that you understand their goal—whether it is to try to cure the cancer or to prevent or treat symptoms. In some cases, regional chemo (where drugs are delivered directly into a certain area, such as the fluid around the brain or into the liver) may be useful as well. Treatment to relieve symptoms depends on where the cancer has spread. For example, pain from bone metastases may be treated with external beam radiation therapy and/or bisphosphonates such as pamidronate (Aredia) or zoledronic acid (Zometa). Most doctors recommend bisphosphonates or denosumab (Xgeva), along with calcium and vitamin D, for all patients whose breast cancer has spread to their bones.
Advanced cancer that progresses during treatment: Treatment for advanced breast cancer can often shrink the cancer or slow its growth (often for many years), but after a time, it stops working. Further treatment at this point depends on several factors, including previous treatments, where the cancer is located, and a woman’s age, general health, and desire to continue getting treatment.
For hormone receptor–positive cancers that were being treated with hormone therapy, switching to another type of hormone therapy sometimes helps. If either letrozole (Femara) or anastrozole (Arimidex) were given, using everolimus (Afinitor) with exemestane may be an option. If hormone drugs stop working, chemo is usually the next step.
If the cancer is no longer responding to one chemo regimen, trying another may be helpful. Many different drugs and combinations can be used to treat breast cancer. However, each time a cancer progresses during treatment it becomes less likely that further treatment will have an effect. HER2-positive cancers that no longer respond to trastuzumab might respond to lapatinib. Lapatinib also attacks the HER2 protein. This drug is often given along with the chemotherapy drug capecitabine (Xeloda), but it can be used with other chemo drugs, with trastuzumab, or even alone (without chemo). Other options for patients with HER2 positive cancers include giving pertuzumab with chemo and trastuzumab and using the drug ado-trastuzumab emtansine. Because current treatments are very unlikely to cure advanced breast cancer, patients in otherwise good health are encouraged to think about taking part in clinical trials of other promising treatments.
Recurrent breast cancer
Cancer is called recurrent when it come backs after treatment. Recurrence can be local (in the same breast or in the mastectomy scar) or in a distant area. Rarely, breast cancer comes back in nearby lymph nodes. This is calledregional recurrence. Cancer that is found in the opposite breast is not a recurrence—it is a new cancer that requires its own treatment.
Local recurrence: Treatment of women whose breast cancer has recurred locally depends on their initial treatment. If the woman had breast-conserving surgery, a local recurrence in the breast is usually treated with mastectomy. If the initial treatment was mastectomy, recurrence near the mastectomy site is treated by removing the tumor whenever possible. This is followed by radiation therapy, but only if none had been given after the original surgery. (Radiation can’t be given to the same area twice.) In either case, hormone therapy, targeted therapy (like trastuzumab), chemo, or some combination of these may be used after surgery and/or radiation therapy.
Regional recurrence: When breast cancer comes back in nearby lymph nodes (such as those under the arm or around the collar bone), it is treated by removing those lymph nodes. This may be followed by radiation treatments aimed at the area. Systemic treatment (like chemo, targeted therapy, or hormone therapy) may be considered after the local treatment as well.
Distant recurrence: In general, women whose cancer comes back in organs like the bones, lungs, brain, etc., are treated the same way as those found to have stage IV breast cancer in these organs when they were first diagnosed (see treatment for stage IV). The only difference is that treatment may be affected by previous treatments a woman has had.
Breast Conservancy Therapy
Marketed in India By :
Incredible Medtech LLP
#D-102 Victoria Garden Tower
M2K Opp. Metro Station Azadpur
Ph.011-46241164 / 23858972 / 9810284657 /9958047250
E.mail : email@example.com